{"filing":{"accession_number":"0001628280-26-054966","cik":"0001598599","ticker":"IPHYF","company_name":"Innate Pharma SA","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"a6kincorporatediph-praug10.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1598599/000162828026054966/a6kincorporatediph-praug10.htm"},"events":[{"id":26278,"run_id":23871,"accession_number":"0001628280-26-054966","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Innate Pharma entered a strategic partnership with Sobi to license lacutamab, granting Sobi exclusive global commercialization rights upon accelerated approval and potential full development rights following positive Phase 3 results. The transaction includes an upfront payment of USD 75 million plus up to USD 505 million in milestone payments and royalties, constituting a material disposition of development and commercialization rights.","company_name":"Innate Pharma SA","ticker":"IPHYF","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27340,"accession_number":"0001628280-26-054966","item_number":"EX-99.1","item_title":"exhibit991.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Innate Pharma entered a strategic partnership with Sobi to license lacutamab, a key asset in the company's pipeline. Under the agreement, Sobi receives exclusive global commercialization rights upon accelerated approval and can assume full development rights following positive Phase 3 results. The transaction involves an upfront payment of USD 75 million plus up to USD 505 million in milestone payments and royalties. This constitutes a material disposition of development and commercialization rights to a partnered asset, which is a form of M\u0026A activity (licensing/disposition) that would materially affect investor assessment of the company's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:07:40.528350+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26279,"run_id":23871,"accession_number":"0001628280-26-054966","anchor_item_number":"EX-99.2","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Innate Pharma appointed Markus Jensen as Chief Medical Officer effective September 1, 2026, succeeding Sonia Quaratino. The appointment is material as it involves a named executive officer role critical to clinical and regulatory execution during a pivotal phase of the company's development.","company_name":"Innate Pharma SA","ticker":"IPHYF","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27341,"accession_number":"0001628280-26-054966","item_number":"EX-99.2","item_title":"exhibit992.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The exhibit announces the appointment of Markus Jensen as Chief Medical Officer effective September 1, 2026, succeeding Sonia Quaratino. While the press release also discloses the Sobi partnership and TELLOMAK-3 Phase 3 advancement, the primary discrete personnel action is the CMO appointment. The appointment is material as it involves a named executive officer role critical to clinical and regulatory execution during a pivotal phase of the company's development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:07:40.528350+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27340,"accession_number":"0001628280-26-054966","item_number":"EX-99.1","item_title":"exhibit991.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Innate Pharma entered a strategic partnership with Sobi to license lacutamab, a key asset in the company's pipeline. Under the agreement, Sobi receives exclusive global commercialization rights upon accelerated approval and can assume full development rights following positive Phase 3 results. The transaction involves an upfront payment of USD 75 million plus up to USD 505 million in milestone payments and royalties. This constitutes a material disposition of development and commercialization rights to a partnered asset, which is a form of M\u0026A activity (licensing/disposition) that would materially affect investor assessment of the company's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:07:40.528350+00:00","company_name":"Innate Pharma SA","ticker":"IPHYF","filing_date":"2026-08-10"},{"id":27341,"accession_number":"0001628280-26-054966","item_number":"EX-99.2","item_title":"exhibit992.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The exhibit announces the appointment of Markus Jensen as Chief Medical Officer effective September 1, 2026, succeeding Sonia Quaratino. While the press release also discloses the Sobi partnership and TELLOMAK-3 Phase 3 advancement, the primary discrete personnel action is the CMO appointment. The appointment is material as it involves a named executive officer role critical to clinical and regulatory execution during a pivotal phase of the company's development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:07:40.528350+00:00","company_name":"Innate Pharma SA","ticker":"IPHYF","filing_date":"2026-08-10"}]}